Novel Bispecific Antibody Tovecimig Shows Efficacy in Biliary Tract Cancer, Though Survival Benefit Remains Ambiguous

By Medical News Desk October 24, 2026 In a significant development for the treatment of aggressive gastrointestinal malignancies, results from the phase II/III COMPANION-002 clinical trial have offered a nuanced…

New Antibody-Drug Conjugate Trastuzumab Rezetecan Shows Promise in HER2-Low Metastatic Breast Cancer

October 23, 2026 — In a significant development for oncology, researchers have unveiled compelling phase III trial data for trastuzumab rezetecan, an investigational antibody-drug conjugate (ADC) demonstrating substantial efficacy in…